

Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Update re. Lab 21 Health and Safety Executive Prosecution

Paris, France, and Manchester, UK - 18 March 2025- Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, provides an update further to the Health and Safety Executive ("HSE") Prosecution announcement made on 21 January 2025 ([RNS: 1680U](#)).

Lab21 Healthcare Ltd ("Lab 21"), a non-trading subsidiary of Novacyt, has pleaded guilty at Exeter Magistrates Court today to health and safety charges relating to the historical operation of its site in Axminster, Devon between 28 June 2018 and 5 April 2019.

The Company has co-operated with the HSE throughout the investigation and the Lab 21 operations no longer form any part of the Novacyt's ongoing business. The lease for the site was originally taken over as part of an acquisition announced on 28 June 2018.

The sentencing hearing is currently planned to be held on the 11 September 2025 to determine the applicable penalty. A further announcement will be made following the outcome.

Contacts

Novacyt SA

Lyn Rees, Chief Executive Officer
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Michael Palser

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com /
y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Paul McManus / Lianne Applegarth
Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

+44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

– Reproductive Health, NMD, Cystic Fibrosis and other rare monogenic disorders

- Reproductive Health: NIP1, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

Research Use Only Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDEVLFFEXLZBBV